OPKO Health (OPK) Competitors

OPKO Health (NASDAQ:OPK) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, community ranking, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

Is OPK or PCRX more profitable?

Pacira BioSciences has a net margin of -13.07% compared to OPKO Health's net margin of -18.65%. Pacira BioSciences' return on equity of 13.42% beat OPKO Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OPKO Health	-18.65%	-9.76%	-6.46%
Pacira BioSciences	-13.07%	13.42%	7.19%

Do analysts rate OPK or PCRX?

OPKO Health presently has a consensus price target of $2.75, indicating a potential upside of 73.03%. Pacira BioSciences has a consensus price target of $23.50, indicating a potential upside of 37.99%. Given OPKO Health's stronger consensus rating and higher possible upside, equities analysts clearly believe OPKO Health is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Pacira BioSciences	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

Do insiders & institutionals have more ownership in OPK or PCRX?

64.6% of OPKO Health shares are owned by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are owned by institutional investors. 47.3% of OPKO Health shares are owned by insiders. Comparatively, 6.4% of Pacira BioSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Which has higher earnings and valuation, OPK or PCRX?

Pacira BioSciences has lower revenue, but higher earnings than OPKO Health. Pacira BioSciences is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$863.50M	1.26	-$188.86M	-$0.19	-8.36
Pacira BioSciences	$674.98M	1.16	$41.96M	-$2.03	-8.39

Does the media favor OPK or PCRX?

In the previous week, Pacira BioSciences had 2 more articles in the media than OPKO Health. MarketBeat recorded 7 mentions for Pacira BioSciences and 5 mentions for OPKO Health. Pacira BioSciences' average media sentiment score of 1.05 beat OPKO Health's score of 0.63 indicating that Pacira BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OPKO Health	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pacira BioSciences	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer OPK or PCRX?

Pacira BioSciences received 318 more outperform votes than OPKO Health when rated by MarketBeat users. Likewise, 71.57% of users gave Pacira BioSciences an outperform vote while only 65.84% of users gave OPKO Health an outperform vote.

Company	Underperform	Outperform
OPKO Health	Outperform Votes 505 65.84%	Underperform Votes 262 34.16%
Pacira BioSciences	Outperform Votes 823 71.57%	Underperform Votes 327 28.43%

Which has more volatility and risk, OPK or PCRX?

OPKO Health has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.

Summary

Pacira BioSciences beats OPKO Health on 10 of the 18 factors compared between the two stocks.